Merrill keeps Amylin at neutral

Merrill Lynch analyst Tom McGahren kept Amylin Pharmaceuticals at its neutral rating following the company's research and development breakfast, which focused on its pipeline candidates for the treatment of obesity. Amylin is considering various combination regimens involving AC137 (pramlintide), AC162352 (synthetic PYY3-36) and leptin. The analyst has seen some encouraging phase 2 data for pramlintide. The challenge seems to be finding the right dose and combination of the drugs. Shares of the San Diego-based biopharmaceutical company were down 88 cents, or 1.92%, at $44.85. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.